Methodology:~Patient screened wil be randomized 2:1 between 2 arms:~Experimental arm: Nivolumab 2 infusions (2 weeks part) before standard of care chemoradiation for 7 weeks with cisplatin at week 1, 4, and 7~Control arm: Standard of care chemoradiation for 7 weeks with cisplatin at week 1, 4, and 7~Primary Objective:~To assess the feasibility and tolerance of neoadjuvant nivolumab treatment before chemoradiation in high-risk HPV-driven Oropharynx Cancer
The aim of this research is to study the feasibility of neoadjuvant treatment before chemoradiation in high risk HPV-driven Oropharynx cancer